Neola Medical (NEOLA) Q3 2024 earnings summary

Executive summary

• Advanced to the clinical validation phase, preparing for a pivotal U.S. clinical study in 2025 for FDA approval and market entry, with a focus on preterm infants and NeolaⓇ.

• Completed a successful human factors study in Boston with U.S. neonatal nurses, supporting the FDA application.

• Achieved CB certificate for safety and performance, and received recognition at the Stanford Pediatric Device Competition.

• Strengthened U.S. presence with new board member, incorporation of a U.S. subsidiary, and expanded board expertise.

• Patent grants in both U.S. and Europe reinforce innovation pipeline and market leadership.

Financial highlights

• Operating expenses increased by 1.8 million SEK year-over-year (Jan–Sep), mainly due to the human factors study and team expansion.

• Development costs totaled 7.4 million SEK for Jan–Sep 2024, up 1.2 million SEK from the previous year.

• Q3 2024 operating income: SEK 0k (0); operating result: SEK -2,476k (-2,540); EPS: -0.04 SEK (-0.05).

• Cash and cash equivalents at period end: SEK 24,161k (26,613); equity ratio at September 30, 2024: 93% (89%); no interest-bearing debt.

• SEK 19,931k raised from new share issues in early 2024, boosting cash position.

Outlook and guidance

• Pivotal U.S. clinical study scheduled for 2025, with pilot study in Sweden as preparation.

• FDA and CE mark submissions targeted for late 2025 and mid-2026, with approvals expected in 2026/2027.

• Market launch targeted for 2026, focusing on U.S. hospitals as primary customers.

• Burn rate expected to rise as clinical validation accelerates and commercial preparations begin.

• Continued focus on building U.S. sales, clinical, and distribution organizations upon positive FDA feedback.